A novel drug combination targeting LSD1 and GSK3 shows promise in treating acute myeloid leukemia by promoting cell ...

April 25, 2025 -- Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib—a differentiated, dual ...

April 25, 2025 -- Allarity Therapeutics, Inc. ("Allarity” or the "Company”) (NASDAQ: ALLR), a Phase 2 clinical-stage ...

CY-101 is a membranolytic inhibitor of the wingless-related integration site (Wnt)/β-catenin pathway. According to the ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Bergen, Norway, April 23, 2025 - Cytovation ASA, a clinical stage oncology company focused on the development of its first-in-class bifunctional peptide CY-101, announces that it has raised NOK62 ...

inhibitor use in cats, specific to Senvelgo (velagliflozin oral solution) and Bexacat (bexagliflozin tablets). She discusses gastrointestinal symptoms, ketosis and diabetic ketoacidosis (DKA), ...

which may have important therapeutic implications for other cancers that are driven by the overactivation of WNT signaling pathway. "Our findings provide compelling evidence to support the testing ...

Porcupine inhibition, targeting the Wnt signaling pathway, shows promise as a treatment for sclerosteosis, a rare genetic disease characterized by excessive bone growth.